AME - Educational Analysis * US Equities
Educational Analysis * US Equities

AME

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerAME
CategoryEducational primer
Last reviewedNovember 10, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

AMETEK, Inc. sits in the Industrials sector under the Electrical Equipment & Parts industry. The company is organized into two operating groups. The Electronic Instruments Group (EIG) designs advanced analytical, test and measurement instruments for the process, aerospace, power and industrial markets. The Electromechanical Group (EMG) supplies precision motion control solutions, highly engineered medical components and devices, thermal management systems, specialty metals and electrical interconnects to aerospace and defense, medical, automation and broader industrial end markets.

The financial footprint of that positioning is reflected in a net margin of 19.9% and ROE of 14.7%. A near-20% net margin in equipment manufacturing typically points to a portfolio that is more differentiated than commoditized: many of AMETEK's instruments and components are engineered into customer systems where specification, reliability and aftermarket support matter. ROE at 14.7% is healthy without being stretched by heavy leverage, suggesting the business compounds capital at a respectable rate through pricing power and operating discipline rather than debt alone. The company also carries a beta of 0.97, essentially market-correlated in terms of systematic risk.

Financial posture

At a market cap of $54.6 billion and a trailing P/E of 33.5, AMETEK trades at a clear premium to the typical industrial multiple. That valuation is backed in part by the 19.9% net margin and 14.7% ROE, but it also implies the market expects durable earnings growth from a mix of organic execution and acquisitions. In fiscal 2025, AMETEK reported $7,401.1 million in sales, up 6.6% from 2024, with diluted EPS of $6.40 up 7.9%. The company also posted record operating income, net income, orders and backlog in that year, which provides context for why investors might assign a higher-than-average multiple. Still, a P/E above 30 leaves little room for execution slips, especially against a backdrop of currency, tariff and aerospace-cycle risks.

Strategic priorities & outlook

AMETEK's own 10-K filing outlines a playbook centered on the AMETEK Growth Model: target high-single-digit annual sales growth, double-digit annual EPS growth, strong cash flow generation, and a superior return on total capital. Operationally, the company pursues lean manufacturing, global sourcing, Design for Six Sigma, Value Engineering/Value Analysis, growth kaizens, digitalization and artificial intelligence under its Operational Excellence initiative.

Acquisitions remain a structural part of the strategy. From 2021 through December 31, 2025, AMETEK completed 15 acquisitions totaling roughly $1.8 billion in annualized sales. In 2025 alone it spent $933.2 million in cash, net of cash acquired, to buy Kern (high-precision machining and optical inspection) and FARO Technologies (3D measurement and imaging). Beyond M&A, AMETEK is expanding globally and in emerging markets, maintaining best-cost manufacturing facilities in China, Czechia, Malaysia, Mexico and Serbia to stay close to customers and support international growth. Geographic dispersion is already meaningful: in 2025, 52% of EIG's net sales and 42% of EMG's net sales went to customers outside the United States, and the company employed approximately 22,500 people as of year-end.

Macro & geopolitical exposure

As an Electrical Equipment & Parts industrial, AMETEK's natural macro exposures include the global manufacturing cycle, aerospace and defense spending, medical capital-equipment demand, and automation investment. The business is sensitive to trade policy and tariff regimes because it manufactures in and ships from multiple jurisdictions, including China, Mexico and Central Europe. Currency translation is another real variable given that roughly half of EIG sales are non-U.S. Commodity prices for copper, steel and specialty metals feed into margins, and supply-chain disruptions can ripple through precision manufacturing lead times. Regulatory risk also matters: medical-device and aerospace customers impose qualification and certification requirements, while defense exposure can bring export-control considerations. These are sector-level dynamics rather than firm-specific judgments, but they frame where AMETEK's results can diverge from headline U.S. industrial activity.

Recent developments

The most recent news flow has been light on negative catalysts. On November 9, 2026, Zacks published analysis of AMETEK's international revenue trends, and on the same day the company announced internal promotions: John Henriques and Kevin Coleman were elevated to Senior Vice Presidents. On November 6, 2026, AMETEK declared its routine quarterly dividend, and on November 4, 2026, Zacks reported that AMETEK's third-quarter 2026 earnings beat estimates on organic sales and margin gains. That headline followed the November 3, 2026 report in which AMETEK delivered actual EPS of $2.21 against an estimate of $2.11, a 4.7% positive surprise.

Earnings behavior & post-earnings drift

AMETEK has been one of the more consistent reporters in its sector. Over the last eight reported quarters, the company beat estimates 8 out of 8 times, for a 100% beat rate, with an average earnings surprise of 4.3%. The average 5-day price move after those reports has been a modest 0.8% upward drift, suggesting that positive surprises have, on balance, been digested with mild follow-through rather than violent repricing.

The four most recent quarters illustrate that consistency does not guarantee a bullish immediate reaction. The November 3, 2026 report ($2.21 vs. $2.11, 4.7% beat) saw the stock fall 4.62% the next day and effectively 0% over the following five sessions. The earlier quarters in 2026 were similarly mixed: August 4 ($2.09 vs. $1.99, 5.0% beat) produced a 0.28% next-day gain and 0.89% over five days; April 30 ($1.97 vs. $1.90, 3.7% beat) saw a 2.13% next-day drop and a 0.33% five-day decline; and February 3 ($2.01 vs. $1.94, 3.6% beat) produced a 0.48% next-day dip but a 1.83% five-day gain. The takeaway is that beating estimates has become the baseline expectation; even solid outperformance can be overshadowed by guidance, valuation or sector rotation. The next report is scheduled for February 2, 2027 before the open, with a consensus EPS estimate of $2.28. As of the current snapshot, the stock is at $238.24, with an RSI of 46.9 and a 50-day EMA of $242.86 sitting above the price.

Frequently Asked Questions

What is AMETEK's earnings beat rate over the last two years?

Over the last eight reported quarters, AMETEK beat consensus EPS estimates in all eight quarters, for a 100% beat rate, with an average surprise of 4.3%.

How does AMETEK say it plans to grow?

The 10-K Growth Model targets high-single-digit annual sales growth and double-digit annual EPS growth, supported by operational excellence, strategic acquisitions and global expansion in regions such as China, Czechia, Malaysia, Mexico and Serbia.

What was AMETEK's most recent quarterly EPS result?

On November 3, 2026, AMETEK reported actual EPS of $2.21 versus a consensus estimate of $2.11, a 4.7% positive surprise.

For a deeper dive into how institutional analysts, quant models and market positioning view AMETEK around the upcoming February 2, 2027 earnings report, readers should consult the full institutional verdict and consensus breakdown on the platform.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 10, 2026
AMETEK, Inc. · Industrials / Electrical Equipment & Parts
$54.6BMarket cap
33.5P/E
19.9%Net margin
14.7%ROE
100%Beat rate, last 8Q
4.3%Avg EPS surprise
0.8%Avg 5-day move after earnings
2027-02-02Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-03$2.21$2.11+4.7%-4.62%null%
2026-08-04$2.09$1.99+5%+0.28%+0.89%
2026-04-30$1.97$1.9+3.7%-2.13%-0.33%
2026-02-03$2.01$1.94+3.6%-0.48%+1.83%
2025-10-30$1.89$1.76+7.4%--
2025-07-31$1.78$1.69+5.3%--

Previous AME editions

Beyond the primer

Get the institutional verdict on AME

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the AME verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.